Palbociclib and letrozole for ER-positive, HER2-negative advanced breast cancer

被引：0
|
作者：
Abraham, Jame
Mechcatie, Elizabeth
机构：
来源：
JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY | 2015年 / 13卷 / 03期
关键词：
D O I：
10.12788/jcso.0113
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：83 / 86
页数：4
相关论文
共 50 条
  • [1] Elacestrant for ER-Positive HER2-Negative Advanced Breast Cancer
    Hageman, Elizabeth
    Lussier, Mia E.
    ANNALS OF PHARMACOTHERAPY, 2024, 58 (08) : 849 - 856
  • [2] Elacestrant in advanced ER-positive, HER2-negative breast cancer
    Kuenzell, Judith Lorenz
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (01) : 16 - 16
  • [3] Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer
    Hoste, G.
    Punie, K.
    Wildiers, H.
    Beuselinck, B.
    Lefever, I.
    Van Nieuwenhuysen, E.
    Han, S. N.
    Berteloot, P.
    Concin, N.
    Salihi, R.
    Vergote, I.
    Neven, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 171 (01) : 131 - 141
  • [4] Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer
    G. Hoste
    K. Punie
    H. Wildiers
    B. Beuselinck
    I. Lefever
    E. Van Nieuwenhuysen
    S. N. Han
    P. Berteloot
    N. Concin
    R. Salihi
    I. Vergote
    P. Neven
    Breast Cancer Research and Treatment, 2018, 171 : 131 - 141
  • [5] Challenges in the management of advanced, ER-positive, HER2-negative breast cancer
    Christopher D. Hart
    Ilenia Migliaccio
    Luca Malorni
    Cristina Guarducci
    Laura Biganzoli
    Angelo Di Leo
    Nature Reviews Clinical Oncology, 2015, 12 : 541 - 552
  • [6] Challenges in the management of advanced, ER-positive, HER2-negative breast cancer
    Hart, Christopher D.
    Migliaccio, Ilenia
    Malorni, Luca
    Guarducci, Cristina
    Biganzoli, Laura
    Di Leo, Angelo
    NATURE REVIEWS CLINICAL ONCOLOGY, 2015, 12 (09) : 541 - 552
  • [7] Palbociclib plus letrozole as first-line treatment for ER-positive and HER2-negative advanced breast cancer in Chinese women: a phase 1 study
    Li, Huiping
    Zhang, Qingyuan
    Li, Wei
    Wang, Shusen
    Liao, Ning
    Shen, Peng
    Shao, Bin
    Zhao, Wenhui
    Sun, Wan
    Yan, Ping
    Wang, Diane
    Li, Vince
    Linn, Carlos
    Shi, Haihong
    O'Gorman, Melissa
    Xu, Binghe
    LANCET ONCOLOGY, 2017, 18 : S7 - S7
  • [8] The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer
    Fjermeros, Kamilla
    Ghannoum, Salim
    Geisler, Stephanie B.
    Bhargava, Sameer
    Tahiri, Andliena
    Klajic, Jovana
    Luders, Torben
    Fongard, Marie
    Nawaz, Meh Sameen
    Bosnjak-Olsen, Tatjana
    Buvarp, Unn-Cathrin Edvardsen
    Johanna Rosenskiold, Aino Katri
    Nguyen, Nam Thi
    Sletbak, Tone Tysko
    Seyedzadeh, Manouchehr
    Selsas, Knut
    Porojnicu, Alina Carmen
    Skjerven, Helle Kristine
    Hovda, Tone
    Sahlberg, Kristine Kleivi
    Torland, Lilly Anne
    Lyngra, Marianne
    Hammarstrom, Clara Louise
    Honigsperger, Elma Bahonjic
    Noone, John Christopher
    Mathiassen, Silje
    Hurtado, Antoni
    Goel, Shom
    Koff, Andrew
    Tekpli, Xavier
    Kristensen, Vessela N.
    Geisler, Juergen
    FUTURE ONCOLOGY, 2024, 20 (32) : 2457 - 2466
  • [9] Endocrine therapy for ER-positive/HER2-negative metastatic breast cancer
    Reinert, Tomas
    de Paula, Bruno
    Shafaee, Maryam Nemati
    Souza, Pedro Henrique
    Ellis, Matthew J.
    Bines, Jose
    CHINESE CLINICAL ONCOLOGY, 2018, 7 (03)
  • [10] Evaluating Elacestrant in the Management of ER-Positive, HER2-Negative Advanced Breast Cancer: Evidence to Date
    Varella, Leticia
    Cristofanilli, Massimo
    ONCOTARGETS AND THERAPY, 2023, 16 : 189 - 196
12345